ValueRx GI disease management drug spend could drop 30% for specific client.
VALUERx GI DISEASE MANAGEMENT DRUG SPEND COULD FALL 30% for one of the pharmacy benefit manager's biggest clients, according to company projections based on previous physician education programs, ValueRx said June 20. ValueRx' gastrointestinal disease management program was initiated for the client in the first quarter of this year, ValueRx reported, and should have results that can be analyzed in the autumn.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth